Seth Forman
MemorialCare Health System(US)Cenex (United Kingdom)(GB)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Allergic Rhinitis and Sensitization, Asthma and respiratory diseases, Food Allergy and Anaphylaxis Research, Autoimmune Bullous Skin Diseases
Most-Cited Works
- → Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa(2016)753 cited
- → Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity(2023)595 cited
- → Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial(2020)460 cited
- → Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis(2021)427 cited
- → Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study(2018)306 cited
- → Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies(2021)281 cited
- → Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study(2019)249 cited
- → Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis(2019)235 cited
- → A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial(2019)168 cited
- → Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa(2021)160 cited